Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Merck (MRK), operating as MSD outside the U.S. and Canada, on Wednesday said it will acquire clinical-stage biotech Terns Pharmaceuticals (TERN) in an all-cash deal valued at approximately $6.7 ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
RAHWAY, N.J., & FOSTER CITY, Calif.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN), a ...
Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor c urrently in Phase 1/2 development for certain patients with CML Merck to hold investor call ...
We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› by Eric C. Evarts After testing more than 75 bike racks, we recommend the Küat ...
Merck & Co. (MRK) is close to an approximately $6 billion all-cash deal to buy U.S. biotech firm Terns Pharmaceuticals (TERN) as it seeks to boost its drug pipeline ahead of cancer treatment ...
The state wants to help more Washingtonians secure a cleaner, less labor intensive ride. The WE-Bike program, in which the Washington State Department of Transportation doles out grants for e-bike ...
Merck MRK-1.03%decrease; red down pointing triangle has reached a nearly $6 billion cash deal to buy the cancer biotech Terns Pharmaceuticals TERN 0.13%increase; green up pointing triangle and its ...
Merck & Co. agreed to buy Terns Pharmaceuticals Inc. for $6.7 billion, giving the multinational company access to a promising new leukemia treatment as it faces the patent expiration of its ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results